Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02528188 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,021
- Enrollment target
NCT02528188 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 3,021 participants.
The verdict
NCT02528188, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,021 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the long-term joint safety and efficacy (pain relief) of the investigational study drug, tanezumab compared to non-steroidal anti inflammatory drugs (NSAIDs) in subjects with osteoarthritis of the hips or knees.
Interventions
- DRUG NSAID
- BIOLOGICAL Tanezumab 2.5 mg
- BIOLOGICAL Tanezumab 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,021 participants |
| Start Date | 2015-07-21 |
| Est. Completion | 2019-02-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02528188
The ClinicalTrials.gov registry entry for NCT02528188 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,021 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which NSAID is the first listed.
NCT02528188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02528188 about?
NCT02528188 is a clinical study titled "Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee". The purpose of this study is to compare the long-term joint safety and efficacy (pain relief) of the investigational study drug, tanezumab compared to non-steroidal anti inflammatory drugs (NSAIDs) in subjects with osteoarthritis of the hips or knees.
What is the current status of trial NCT02528188?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,021 participants. The study started on 2015-07-21. Estimated completion is 2019-02-27.
What interventions are being tested in trial NCT02528188?
The interventions under investigation include: NSAID (DRUG), Tanezumab 2.5 mg (BIOLOGICAL), Tanezumab 5 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02528188?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.